Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The bill would require MassHealth to cover FDA-approved anti-obesity medications (including Wegovy, Saxenda, and Zepbound) for any enrollee with: BMI 30, or BMI 27 with at least one weight-related comorbidity The bill includes a fiscal note estimating first-year cost of $680 million, assuming 6% uptake among eligible enrollees
Retrieved from Leehey, D
Semaglutide uniquely addresses the psychological and neurological drivers of overeating
Effects on alcohol use disorder Alcohol use disorder is associated with substantial mortality and global disease burden, and there are various medications that have shown limited success in treating these disorders, such as naltrexone and acamprosate
